|
Fourth Drug for Treatment of Alzheimer's Disease AvailableOn February 28, 2001, the United States Food and Drug Administration (FDA) approved galantamine hydrobomide (Reminyl �), the fourth drug marked specifically to treat symptoms of mild to moderate Alzheimer's. In clinical trials comparing galantamine to placebo (inactive treatment), participants receiving galantamine showed better results in measures of thinking and reasoning, daily functioning and behavior. Like other approved Alzheimer drugs, galantamine is a cholinesterase inhibitor. This class of drugs temporarily increases the brain's supply of acetylcholine, a nerve messenger chemical that becomes deficient in the Alzheimer brain as cell death progresses. This drug, produced by Janssen Pharmaceuticals, became available in pharmacies in May 2001. For a fact sheet about galantamine or cholinesterase inhibitors in general, call the National Capital Area toll-free Helpline at 1-866-259-0042.
(Advances, Summer 2001, National Alzheimer's Association)
|
© 1997 - 2002 Alzheimer's Association, National Capital Area. All rights reserved.